NCT03460977 2026-03-13
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
Clinical Trials
26 trialsNCT04221542 2026-03-06
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
Phase 1 Recruiting
NCT06257693 2026-02-27
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
Alessa Therapeutics Inc.
Phase 1 Recruiting
NCT05997615 2026-02-24
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT05818683 2026-02-13
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT04729114 2026-02-04
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Astellas Pharma Inc
Phase 1 Recruiting
NCT07277270 2026-01-07
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Recruiting
NCT05413421 2025-08-11
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
ORIC Pharmaceuticals
Phase 1 Recruiting
NCT02204072 2025-07-15
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Boehringer Ingelheim
Phase 1 Completed
NCT04094519 2024-11-20
A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
Astellas Pharma Inc
Phase 1 Completed
NCT03776968 2024-10-23
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
Hinova Pharmaceuticals Inc.
Phase 1 Completed
NCT06332170 2024-07-18
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT03685591 2024-06-26
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT03569280 2023-07-18
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
Kangpu Biopharmaceuticals, Ltd.
Phase 1 Completed
NCT04179396 2023-06-29
RAMP
pharmaand GmbH
Phase 1 Completed
NCT04087174 2022-07-13
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
AstraZeneca
Phase 1 Completed
NCT01362374 2022-01-12
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT03774056 2020-11-03
A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.
Hinova Pharmaceuticals Inc.
Phase 1 Completed
NCT03778047 2020-11-03
A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch
Hinova Pharmaceuticals Inc.
Phase 1 Completed
NCT02215096 2020-10-22
Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
GlaxoSmithKline
Phase 1 Completed
NCT01597193 2019-05-08
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Pfizer
Phase 1 Completed
NCT02225093 2017-06-27
A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer
Astellas Pharma Inc
Phase 1 Completed
NCT01911728 2017-06-26
Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates
Astellas Pharma Inc
Phase 1 Completed
NCT02380313 2016-10-06
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
GlaxoSmithKline
Phase 1 Withdrawn
NCT01902251 2014-09-09
Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients
Astellas Pharma Inc
Phase 1 Completed
NCT01911741 2013-07-30
A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects
Astellas Pharma Inc
Phase 1 Completed